<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03124511</url>
  </required_header>
  <id_info>
    <org_study_id>DOLORISK-BREAST</org_study_id>
    <nct_id>NCT03124511</nct_id>
  </id_info>
  <brief_title>Neuropathic Pain After Breast Surgery</brief_title>
  <official_title>DOLORISK: Understanding Risk Factors and Determinants for Neuropathic Pain - Neuropathic Pain After Breast Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Danish Pain Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>DOLORISK Consortium</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Aarhus University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Danish Pain Research Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To understand pain pathophysiology in terms of risk factors and protective mechanisms ranging
      from molecular pathways to societal impacts.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pain and loss of function are intimately associated with the reaction of the nervous system
      to neural damage. A lesion to the somatosensory nervous system caused by mechanical trauma,
      metabolic disease, neurotoxic chemicals, infection or tumor invasion may give rise to
      neuropathic pain. Neuropathic pain affects around 8% of the population and may negatively
      impact the individual's quality of life; moreover, the condition leads to significant costs
      to the healthcare system and society. Not all subjects with such a lesion develop neuropathic
      pain, and those who do develop neuropathic pain have varying degrees of symptom severity,
      impact and outcomes and may respond unpredictably to treatment.

      The interaction between genetics and environmental and clinical factors in a susceptible
      individual most likely contribute to the variation in pain prevalence and severity. A better
      understanding of the exact nature of these risk factors and their interactions will
      ultimately improve the patients' health, both in terms of recognizing patients at risk and
      identifying new treatment modalities.

      Genetic, neurophysiological and psychological factors all influence the risk of developing
      persistent pain. It is therefore possible to describe a genetic, neurophysiological and
      psychological profile, in particular in patients experiencing neuropathic pain after surgery
      and/or neurotoxic chemotherapy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 15, 2017</start_date>
  <completion_date type="Anticipated">November 2019</completion_date>
  <primary_completion_date type="Anticipated">November 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Chronic neuropathic pain, postoperative</measure>
    <time_frame>12 months after surgery</time_frame>
    <description>Neuropathic pain grading system; Finnerup et al. 2016 will be used.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Chronic chemotherapy-induced peripheral neuropathy</measure>
    <time_frame>12 months after surgery</time_frame>
    <description>For case definition of neuropathy Tesfaye et al. 2010 will be used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chronic chemotherapy-induced neuropathic pain</measure>
    <time_frame>12 months after surgery</time_frame>
    <description>Neuropathic pain grading system; Finnerup et al. 2016 will be used.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">275</enrollment>
  <condition>Chronic Neuropathic Pain, Postoperative</condition>
  <condition>Chronic Pain, Postoperative</condition>
  <condition>Chronic Chemotherapy-induced Neuropathic Pain</condition>
  <condition>Chronic Chemotherapy-induced Pain</condition>
  <condition>Chronic Chemotherapy-induced Peripheral Neuropathy</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Surgery for breast cancer</intervention_name>
    <description>Breast cancer resection performed via lumpectomy or mastectomy with or without sentinal node biopsy and axillary lymph node dissection.</description>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients scheduled for breast cancer resection at the Department of Breast Surgery, Aarhus
        University Hospital, Aarhus, Denmark.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients scheduled for breast cancer resection performed via lumpectomy (partial or
             segmental mastectomy) or mastectomy with or without sentinel lymph node biopsy and
             axillary lymph node dissection, and any combinations hereof.

          -  Willingness and ability to comply with study procedures as judged by the site
             investigator/manager.

          -  Expected availability for follow-up throughout the study, i.e., ~12 months.

          -  Willingness to voluntarily sign and date the study-specific informed consent form.

        Exclusion Criteria:

          -  Mental incapacity or language barriers precluding adequate understanding of study
             procedures.

          -  Current alcohol or substance abuse according to the site investigator's medical
             judgement.

          -  Unsuitability for participation in the study for any other reason, e.g. due to a
             significant serious underlying condition (e.g. other cancer or AIDS), as determined by
             the site investigator/manager.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nanna B Finnerup, DMSc</last_name>
    <role>Study Director</role>
    <affiliation>Danish Pain Research Center, Aarhus University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kasper Grosen, PhD</last_name>
    <phone>+45 78463287</phone>
    <email>kasper.grosen@clin.au.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nanna B Finnerup, DMSc</last_name>
    <phone>+45 78464230</phone>
    <email>finnerup@clin.au.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Danish Pain Research Center, Aarhus University Hospital</name>
      <address>
        <city>Aarhus C</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kasper Grosen, PhD</last_name>
      <phone>+45 78463287</phone>
      <email>kasper.grosen@clin.au.dk</email>
    </contact>
    <contact_backup>
      <last_name>Helle O Andersen</last_name>
      <phone>+45 78463380</phone>
      <email>hoand@clin.au.dk</email>
    </contact_backup>
    <investigator>
      <last_name>Kasper Grosen, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nanna B Finnerup, DMSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lone Nikolajsen, DMSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kristine J Bennedsgaard, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lise Ventzel, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hanne Rønning, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Inge S Andersen, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Breast Surgery, Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hanne Rønning, MD</last_name>
      <phone>+45 78465105</phone>
      <email>hannroen@rm.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Breast Surgery Clinic, Viborg Regional Hospital</name>
      <address>
        <city>Viborg</city>
        <zip>8800</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Inge S Andersen, MD PhD</last_name>
      <phone>+45 7844 6360</phone>
      <email>ingander@rm.dk</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <link>
    <url>http://www.dolorisk.eu</url>
    <description>DOLORisk Project Website</description>
  </link>
  <reference>
    <citation>Tesfaye S, Boulton AJ, Dyck PJ, Freeman R, Horowitz M, Kempler P, Lauria G, Malik RA, Spallone V, Vinik A, Bernardi L, Valensi P; Toronto Diabetic Neuropathy Expert Group. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care. 2010 Oct;33(10):2285-93. doi: 10.2337/dc10-1303. Review. Erratum in: Diabetes Care. 2010 Dec;33(12):2725.</citation>
    <PMID>20876709</PMID>
  </reference>
  <reference>
    <citation>Finnerup NB, Haroutounian S, Kamerman P, Baron R, Bennett DL, Bouhassira D, Cruccu G, Freeman R, Hansson P, Nurmikko T, Raja SN, Rice AS, Serra J, Smith BH, Treede RD, Jensen TS. Neuropathic pain: an updated grading system for research and clinical practice. Pain. 2016 Aug;157(8):1599-606. doi: 10.1097/j.pain.0000000000000492. Review.</citation>
    <PMID>27115670</PMID>
  </reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 19, 2017</study_first_submitted>
  <study_first_submitted_qc>April 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 21, 2017</study_first_posted>
  <last_update_submitted>October 5, 2017</last_update_submitted>
  <last_update_submitted_qc>October 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chronic Pain</mesh_term>
    <mesh_term>Neuralgia</mesh_term>
    <mesh_term>Peripheral Nervous System Diseases</mesh_term>
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

